Entellus Medical to Present at the Canaccord Genuity Annual Growth Conference

PLYMOUTH, Minn., July 26, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the less invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction, and persistent Eustachian tube dysfunction, today announced the Company plans to participate in the 37^th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.

Entellus Medical’s management is scheduled to present on Wednesday, August 9, 2017 at 8:30am ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website.

About Entellus Medical, Inc.

Entellus is a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatments. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, patients with nasal airway obstruction as well as adult patients with persistent Eustachian tube dysfunction. The Entellus platform of products provides safe, effective and easy-to-use solutions intended to enable treatment of patients in more cost-effective sites of care. Entellus’ product lines including the XprESS™ ENT Dilation System, Latera™ Absorbable Nasal Implant, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the most cost effective and efficient site of care. Entellus is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.

Contact: Lynn Pieper Lewis
415-937-5402
[email protected]